{"id":126719,"date":"2025-08-07T15:58:10","date_gmt":"2025-08-07T15:58:10","guid":{"rendered":"https:\/\/www.europesays.com\/us\/126719\/"},"modified":"2025-08-07T15:58:10","modified_gmt":"2025-08-07T15:58:10","slug":"biotech-blues-the-west-struggles-to-stay-ahead","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/126719\/","title":{"rendered":"Biotech Blues: The West Struggles To Stay Ahead"},"content":{"rendered":"

American Jennifer Doudna and Frenchwoman Emmanuelle Charpentier won<\/a> the 2020 Nobel Prize for discovering the CRISPR\/Cas9 genetic scissors. With these revolutionary tools, researchers can edit DNA sequences in living cells, with profound implications for the future of research, medicine, and agriculture.\u00a0<\/p>\n

But it is not the US or Europe that is making the most of this breakthrough. China is. Over the past two decades, China has gone from a peripheral player to a frontrunner in synthetic biology<\/a>, AI-enhanced drug discovery, and genomic data infrastructure.\u00a0\u00a0<\/p>\n

Between 2007 and 2017, China\u2019s biotech publications grew<\/a> at an average annual rate of 20%. In 2020, Chinese research surpassed<\/a> that of Germany and the United Kingdom in quality, as measured by the Nature Index. In biotechnology patents, China\u2019s global share rose<\/a> from just 1% in 2000 to 28% in 2019, while the American share declined from 45% to 27%. Today, China is responsible<\/a> for 40% of the global production of active pharmaceutical ingredients.\u00a0<\/p>\n

While the US remains a biotech superpower, its lead is no longer secure. In China, government funding provides a strong <\/a>and steady stream of investment, compared to the US and Europe, which rely on private R&D and venture capital. The US Congress has yet to craft a unified biotechnology strategy. Venture capital funding, while robust, remains volatile.\u00a0\u00a0<\/p>\n

Meanwhile, China\u2019s model\u2014top-down, long-term, and state-backed\u2014is gaining ground. Beijing has declared<\/a> synthetic biology a strategic priority, woven it into successive Five-Year Plans, and funneled billions into genome sequencing, bio-manufacturing, and AI-enhanced drug development.\u00a0 In 2023 alone, China spent<\/a> $15 billion on biopharmaceutical R&D, up from just $35 million in 2015.\u00a0\u00a0<\/p>\n

Admittedly, the US remains the undisputed global biotech nation, thanks to premier research institutions and strong private R&D investment. The US continues<\/a> its lead in biotech patents, with 39% of total biotech patents in 2020, followed by the European Union with 18% share, and China at 10%.\u00a0\u00a0<\/p>\n

But China is catching up fast. Chinese companies such as BGI Genomics and Sinovac Biotech are globally recognized. BGI played a central role in sequencing<\/a> the SARS-CoV-2 genome in record time, catalyzing vaccine development. Others, like Ping An Good Doctor, apply AI to diagnostic support and telemedicine, expanding<\/a> access in underserved regions. Chinese researchers have used synthetic biology to engineer<\/a> yeast for pharmaceuticals and crops for resilience, while tech giants Tencent, Baidu, and Alibaba invest heavily in AI-driven healthcare.\u00a0<\/p>\n

Gene-editing tools like CRISPR-Cas9<\/a> are flourishing in China. In 2018, a Chinese scientist successfully edited<\/a> embryos to resist HIV using CRISPR. While this gene editing experiment on humans (though successful) was highly controversial<\/a> globally as well as in China, it revealed a stark asymmetry: Chinese scientists are pushing the envelope where others hesitate.\u00a0\u00a0<\/p>\n

In contrast, American and European researchers face regulatory gridlock, an anti-science backlash, and a lack of sustained funding. In the US, religious and ethical concerns are also a significant hurdle.\u00a0 The Dickey-Wicker Amendment<\/a>, enacted in 1996, prohibits the use of federal funds for research that involves the creation or destruction of human embryos. Consistent with this restriction, the National Institute of Health will not support<\/a> any research involving gene editing in human embryos.\u00a0<\/p>\n

The new Trump Administration looks set to expand these restrictions. Robert Kennedy Jr., the Secretary of Health and Human Services, is a vocal champion<\/a> of \u201cnatural\u201d approaches to health. His skepticism of what he sees as \u201cunnatural\u201d interventions shapes his opposition to technologies such as CRISPR and genetically modified crops.\u00a0<\/p>\n

CRISPR-edited crops have also become a casualty of Europe\u2019s fear and wariness toward genetic modification. In 2018, the European Court of Justice ruled<\/a> that crops created using new gene-editing tools like CRISPR should be regulated as GMOs. That decision has all but barred them from the European market.\u00a0<\/p>\n

\n\t\t\tGet the Latest\t\t<\/p>\n

\n\t\t\tSign up to receive regular Bandwidth emails and stay informed about CEPA’s work.\t\t<\/p>\n

Complicated pricing and regulatory frameworks represent additional hurdles. New medicines take<\/a> longer to get approved in the European Union than in other regions, with the average approval time at 430 days as of 2022. After a drug is approved, each of the 27 EU countries has its own process to decide whether to buy the medicine, and at what price.\u00a0<\/p>\n

In contrast, medicines made in China, or not yet approved abroad, are fast-tracked<\/a> for review. Companies enjoy long data exclusivity\u2014protection from generic competition\u2014if clinical trials are done in China and the drug hasn\u2019t been approved in other countries.\u00a0<\/p>\n

A similar dynamic plays out with another leading biotech innovation: CAR-T therapy<\/a>, which reprograms immune cells to target cancers. American labs pioneered<\/a> the field and launched<\/a> their first commercial drugs. Yet China now leads<\/a> in the number of approved CAR-T therapies and clinical trials, benefiting from fast-tracked regulatory approvals, vast patient datasets, and government-subsidized innovation hubs.\u00a0<\/p>\n

The US created the AI biotech revolution. In 2020, Google DeepMind\u2019s AlphaFold<\/a> solved the \u201cprotein folding problem<\/a>,\u201d explaining how a string of amino acids twists itself into the intricate three-dimensional shape of a functioning protein. For decades, unlocking this mystery required years of painstaking lab work. DeepMind\u2019s AlphaFold<\/a> cracked the code with AI, allowing it to predict a protein\u2019s 3D structure in minutes. AlphaFold is now a backbone of precision medicine<\/a>, speeding up drug discovery, aiding vaccine development, and enabling the design of therapies tailored to an individual\u2019s molecular makeup.\u00a0<\/p>\n

Multinational pharmaceutical companies are investing record sums in early-stage medicines from Chinese biotech firms. Chinese companies account<\/a> for 18% of global licensing deals. These agreements typically grant foreign firms rights to develop and sell Chinese-discovered therapies abroad, with Chinese companies earning more as drugs advance through trials.\u00a0<\/p>\n

Beneath these scientific advances lies a foundational resource: genomic data\u2014the most valuable commodity in biomedical research.\u00a0 By analyzing genetic variations across massive populations, AI systems detect disease patterns, design targeted therapies, and predict adverse drug reactions.\u00a0\u00a0<\/p>\n

Through initiatives like Made in China 2025<\/a> and a $9 billion precision medicine project<\/a>, Chinese companies are collecting, processing, and analyzing genetic data at scale. During the COVID-19 pandemic, China\u2019s BGI Genomics distributed<\/a> testing kits to 180 countries and established labs in 18 countries, creating global channels for data acquisition.\u00a0\u00a0<\/p>\n

Through a series of cyber breaches, China has acquired personal and health information on hundreds of millions of people around the globe. Under Chinese law, firms must share any collected data with the state. There is no opt-out. That makes Chinese companies not just market actors, but potential instruments of state power.\u00a0<\/p>\n

Imagine a cancer patient in the US whose best hope for survival lies in a personalized therapy developed by a Chinese biotech company. The treatment requires sharing the patient\u2019s genetic information. The patient, desperate for a cure, consents.\u00a0\u00a0<\/p>\n

Americans might be willing to share their most intimate biological and genetic information to save their lives\u2014even if that data becomes part of a strategic asset, potentially owned and controlled by a geopolitical rival. In such scenarios, national security concerns could become personal.\u00a0<\/p>\n

The US and Europe must act to ensure their biotech leadership. They should fund early-stage AI-driven startups and ensure ethical guardrails evolve alongside scientific advances. Immigration policy must also attract and keep skilled talent.\u00a0<\/p>\n

At stake is more than a contest over patents or profits. It is a struggle over who gets to define the boundaries of the bioeconomy.\u00a0 If the US and Europe fail to lead, the next generation of breakthrough therapies may not emerge from Boston or Basel\u2014but from Beijing or Shenzhen.\u00a0\u00a0<\/p>\n

Elly Rostoum is a Google Public Policy Fellow with the Center for European Policy Analysis (CEPA). She is a Lecturer at Johns Hopkins University. You can find out more about her work here: www.EllyRostoum.com<\/a>\u00a0<\/p>\n

Bandwidth<\/a> is CEPA\u2019s online journal dedicated to advancing transatlantic cooperation on tech policy. All opinions expressed on Bandwidth are those of the author alone and may not represent those of the institutions they represent or the Center for European Policy Analysis.\u00a0CEPA maintains a strict intellectual independence policy across all its projects and publications.<\/p>\n

\t\t\t\t\t\t\t<\/p>\n

\t\t\t\t\t\t<\/p>\n

\t\t\t\t\t\t\t\t\t\t\t\t<\/a><\/p>\n

\n\t\t\tRead More From Bandwidth\t\t<\/p>\n

\n\t\t\tCEPA\u2019s online journal dedicated to advancing transatlantic cooperation on tech policy.\t\t<\/p>\n

\t\t\t\t\t
\n\t\t\t\tRead More\t\t\t<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"American Jennifer Doudna and Frenchwoman Emmanuelle Charpentier won the 2020 Nobel Prize for discovering the CRISPR\/Cas9 genetic scissors.…\n","protected":false},"author":3,"featured_media":126720,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[815,159,67,132,68],"class_list":{"0":"post-126719","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-genetics","9":"tag-science","10":"tag-united-states","11":"tag-unitedstates","12":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114988312350712782","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/126719","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=126719"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/126719\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/126720"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=126719"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=126719"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=126719"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}